bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 2004: Epigenetic targeting of CD276 expression in medullolbastoma
Authors: Guda Maheedhara R. , Castellanos Jose R. , Labak Collin M. , Sanam Ramadevi , Daniels David J. , Martin Sarah E. , Lin Julian J. , Tsung Andrew J. , Velpula Kiran K. , Asuthkar Swapna 
Published: July 2017

Abstract
Medulloblastoma (MB) is the most common malignant brain tumor in children and accounts for 20% of pediatric CNS tumors. Following surgery and treatment with chemotherapy and radiation, MBs recur in a significant proportion of patients. Moreover, survivors experience comorbidities related to the tumor and/or its treatment. New insights into MB tumor pathogenesis are needed for improving the survivorship and outcome of MB. Epigenetic silencing, including histone modification and DNA methylation, is an important tumorigenic mechanism in MB. However, its role in cancer immunopathology is poorly understood. Using datamining and immunohistochemistry analysis, we show that B7-H3 (CD276), an important immune checkpoint member of the B7 and CD28 families, is highly upregulated in all four molecular subtypes of MB compared to normal tissue. Based on the clinical success of inhibitory immune checkpoint blockades (CTLA-4, PD-1, and PD-L1), CD276 appears to be a promising therapeutic target for cancer immunotherapy. Moreover, we observed that increased expression of CD276 correlates significantly with the expression of Enhancer of Zeste Homologue 2 (EZH2), a histone H3-methylating (H3K27me3) catalytic subunit in the human MB specimens. We hypothesize that combined targeting of CD276 and EZH2 may have greater impact on tumor progression and immune cell response in MB. Simultaneously, we performed LC/MS analysis to identify novel interaction partners of CD276 in MB tumor. These findings taken together suggest that CD276 is strongly associated with several epigenetic markers, indicating a strong relationship between cancer immune evasion and epigenetic mechanisms.
Citation Format: Maheedhara R. Guda, Jose R. Castellanos, Collin M. Labak, Ramadevi Sanam, David J. Daniels, Sarah E. Martin, Julian J. Lin, Andrew J. Tsung, Kiran K. Velpula, Swapna Asuthkar. Epigenetic targeting of CD276 expression in medullolbastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2004. doi:10.1158/1538-7445.AM2017-2004
Abstract 2014: Genitourinary cancer-derived cells produce microenvironment proteinases that regulate proteinase activated receptors (PARs) to drive oncogenic signaling
Authors: Gibson Stacy G. , Mihara Koichiro , Zijlstra Andries , Hyndman Matthew E. , Hollenberg Morley D. 
Published: July 2017

Abstract
Background:
Thrombin-triggered activation of proteinase-activated receptor-1 (PAR1) is recognized as a key stimulus for driving epithelial malignancies (IUBMB life.63:397, 2011; PMID:21557443). However, the enzymes for regulating PAR1 in the tumour microenvironment are not known.
Hypothesis:
We hypothesize that prostate (PC) and urinary bladder cancer (UBC) cells can regulate microenvironment signaling to drive cancer progression via the secretion of proteinases that cleave/regulate proteinase-activated receptors (PARs).
Aims:
1.) Visualize the cleavage status of N- and C-terminally-dual-labelled PARs in receptor-transfected UBC- and PC-derived cells.
2.) Measure PAR cleavage by UBC and PC-secreted proteinases.
3.) Identify the UBC & PC-derived proteinases that cleave/regulate PAR function.
Methods:
The cleavage status of dual-labeled PARs (N-terminus-mCherry/C-terminus-YFP) expressed in PC & UBC cells was determined by confocal image analysis as already described (JBC 288:32979, 2013; PMID: 26957205). Intact receptors look 'yellow' and cleaved receptors look 'green'. The cleavage of PARs in UBC and PC cells was studied for dual-tagged-PAR-expressing UBC and PC cells exposed or not to cell-derived culture supernatants, enzyme agonists for PAR1 and 2 (thrombin and trypsin, respectively), and proteinase inhibitors (e.g. for MMPs and other enzymes). The impact of CRISPR-mediated elimination of MMPs from PC3 cells on PAR1 cleavage status was also monitored.
Results:
UBC- and PC-produced enzymes can cleave PAR1 as efficiently as thrombin, an established PAR1 agonist. None of the UBC cell lines produce proteinases that cleave PAR2. Inhibition of MMP activity partially prevents PAR1 cleavage by UBC cells and completely prevents PAR1 cleavage in PC3-PC cells.
Conclusions:
We conclude that UBC and PC cells secrete PAR-regulating proteinases that can directly regulate PAR1 in the tumour microenvironment so as to drive cancer progression.
Funding:
Alberta Innovates CRIO Grant, Prostate Cancer Canada Discovery Grant, Motorcycle Ride for Dad, Johnson & Johnson Alberta Health Partnership and CIHR
Note: This abstract was not presented at the meeting.
Citation Format: Stacy G. Gibson, Koichiro Mihara, Andries Zijlstra, Matthew E. Hyndman, Morley D. Hollenberg. Genitourinary cancer-derived cells produce microenvironment proteinases that regulate proteinase activated receptors (PARs) to drive oncogenic signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2014. doi:10.1158/1538-7445.AM2017-2014
Abstract 2015: Mesenchymal stem cell correlates oral leukoplakia malignant transformation through regulate T cell response
Authors: Chen Yichen , He Bailin , Ma Da , Song Jingjing , Wang Xi , Cheng Bin , Wang Zhi 
Published: July 2017

Abstract
Introduction
Leukoplakia is one of the most common clinically presented oral potential malignant disorders (OPMD). Detailed understanding of leukoplakia-associated molecular or cellular changes would help us better undertand about the progress of leukoplakia malignant transformation. In this study, we examined the potential involvement of MSC in this very progress, and demonstrated lesion resident MSCs may favour leukoplakia malignant transformation through its strong immunoregulation on T cell.
Methods
Eighteen six-week-old female Sprague-Dawley rats (180-220g) were given 0.05g/L 4NQO in drinking water for 22 weeks for development of lesions. Lesions classfied by histological HE stainnig. MSCs were obtained from single cell suspesion of lesions, and cultured with splenocyte to study its immunoregulate ability.
Results
1. MSC-like cells are enriched in carcinogen induced leukoplakia and cancers. Representative results showing the lesions on tongue of rats. And relative proportion of MSC phenotype marker (CD29+, CD31-, CD45-, CD90+) in oral lesions (OMSC) were counted by flow cytometry.
2. Leukoplakia-derived MSC (L-OMSC), cancer-derived MSC (C-OMSC), and the normal mucosa-derived MSC (N-OMSC) share the similar stemness properties.
3. Cancer lesion have less infiltrating T cells (quantified by IHC and FCM of CD3 ). Cancer-derived MSCs suppress T cell proliferation, but not promote T cell apoptosis and inhibit T cell migration to the lesions.
4. Higher number of lesion derived MSCs associates with higher celluar proliferation in the lesions.
Summary
Our study demonstrated MSCs could migrate to pre-malignant leukoplakia lesions prior to tumor establishment. Further, MSCs play an important role in leukoplakia malignant transformation induced by chemicals, which via its strong immunomodulatory activities.
Citation Format: Yichen Chen, Bailin He, Da Ma, Jingjing Song, Xi Wang, Bin Cheng, Zhi Wang. Mesenchymal stem cell correlates oral leukoplakia malignant transformation through regulate T cell response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2015. doi:10.1158/1538-7445.AM2017-2015
Abstract 2020: Synergistic induction of apoptosis of combined mesupron and auranofin treatment in human breast cancer cells
Authors: Lee Joo-Eun , Kwon Yeo-Jung , Oh Kyung-Soo , Chun Young-Jin 
Published: July 2017

Abstract
Urokinase-type plasminogen activator (uPA) system may play a crucial role in cancer cell invasion and metastasis. uPA has been validated as a predictive or prognostic biomarker protein and considered as a therapeutic target in human breast cancer. Mesupron is a uPA inhibitor blocking uPA enzymatic activity to reduce tumor cell invasion, migration and cell growth. Auranofin has been known as an antirheumatic drug and a thioredoxin reductase inhibitor and recently its anticancer activity in ovarian and breast cancers has also been identified. To study whether cotreatment with mesupron and auranofin shows a significant anticancer activity, the synergistic induction of apoptosis of mesupron with auranofin was determined. Auranofin or mesupron alone inhibited cancer cell growth in MCF-7 cells with IC50 of 0.25 μM or 25 μM, respectively. Flow cytometric analysis also showed an increased apoptosis. When cells were treated with mesupron (0.125 μM) in combination with auranofin (10 μM), we found a significant induction of apoptosis although the cytotoxic effects of mesupron or auranofin alone at those concentrations were not quite strong. Interestingly, combined mesupron and auranofin treatment significantly suppressed mitochondrial antiapoptotic proteins including Bcl-2 and Bcl-xL. We also found the increase of caspase-3 and PARP cleavages. The combination index (CI) also indicated the synergistic induction of apoptosis by auranofin and mesupron. Taken together, these data suggest that the use of mesupron and auranofin in combination can be valuable to achieve higher anticancer activity.
Note: This abstract was not presented at the meeting.
Citation Format: Joo-Eun Lee, Yeo-Jung Kwon, Kyung-Soo Oh, Young-Jin Chun. Synergistic induction of apoptosis of combined mesupron and auranofin treatment in human breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2020. doi:10.1158/1538-7445.AM2017-2020
Abstract 2024: Reactivating apoptosis in BFL-1/A1 driven cancer with cysteine-reactive stapled peptide inhibitors
Authors: Guerra Rachel M. , Huhn Annissa J. , Harvey Edward P. , Bird Gregory H. , Walensky Loren D. 
Published: July 2017

Abstract
BFL-1/A1 is a BCL-2 family protein implicated in the progression and chemoresistance of melanoma, lymphoma, and other cancers, yet it remains undrugged. Anti-apoptotic BCL-2 family proteins block cell death by trapping the critical α-helical BH3 domains of pro-apoptotic members in a surface groove. Cancer cells hijack this survival mechanism by overexpressing a spectrum of anti-apoptotic members, mounting formidable apoptotic blockades that resist chemotherapeutic treatment. Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest-priority goal, fueled by the clinical success of venetoclax, a selective BCL-2 inhibitor, in reactivating apoptosis in BCL-2-dependent cancers. A natural juxtaposition of two unique cysteines at the binding interface of the NOXA BH3 helix and BFL-1/A1 pocket informed the development of stapled BH3 peptides bearing acrylamide warheads to irreversibly inhibit BFL-1/A1 by covalent targeting. Here, we describe the development and application of cysteine-reactive stapled peptides that, compared to their non-covalent analogs, trigger rapid mitochondrial cytochrome c release, caspase 3/7 activation, and apoptosis induction of BFL-1/A1 driven cancers such as melanoma. Mechanism of action studies demonstrated the exquisite BFL-1/A1 selectivity and mitochondrial localization of the in situ covalent reaction. Given the frequent proximity of native cysteines to regulatory binding surfaces, covalent stapled peptide inhibitors provide a new therapeutic strategy for targeting oncogenic protein interactions.
Citation Format: Rachel M. Guerra, Annissa J. Huhn, Edward P. Harvey, Gregory H. Bird, Loren D. Walensky. Reactivating apoptosis in BFL-1/A1 driven cancer with cysteine-reactive stapled peptide inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2024. doi:10.1158/1538-7445.AM2017-2024
Abstract 2034: LSD1 inhibition alone and in combination with chemotherapy in Ewing sarcoma cell lines
Authors: Welch Darcy , Kahen Elliot , Cubitt Christopher L. , Reed Damon R. 
Published: July 2017

Abstract
Background: Ewing Sarcoma (ES) is the second most common primary bone cancer affecting children and young adults. Despite advances in treatment that have led to survival rates of approximately 73% for localized disease, outcomes for patients with metastatic or recurrent ES remain poor. A distinguishing feature of ES is the presence of the EWS/FLI1 fusion in 85% of cases. The fusion has been shown to alter expression of a number of oncogenic genes. Mechanistic studies have demonstrated that the NuRD co-repressor complex interacts with EWS/FLI1. The associated protein LSD-1 contributes to the repressive function by histone modifications. While reversible LSD1 inhibitors demonstrate single agent activity, in preclinical models, a system to evaluate combinations may be needed for optimizing effect in clinical trials.
Methods: Here, we seek to confirm promising single drug activity and evaluate combination therapies using active chemotherapies currently utilized in ES care (4-HC, etoposide, SN-38, vincristine and doxorubicin) along with the LSD1 Inhibitors SP2509 and SP2577 and romidepsin, an HDAC inhibitor. We evaluated these combinations in high-throughput screening platforms and well-established cell line models for ES (A-673, TC-32, RD-ES, TC-71). Taking into consideration past lessons learned from in vitro experiments, we designed stringent screening conditions that assess the candidate compounds and combinations at clinically-relevant concentrations and exposure times that mimic the in vivo pharmacokinetics in an effort to maximize the translational potential of these results to the clinical setting. All combinations of agents were studied in two-drug combinations to evaluate for synergy in addition to efficacy.
Results: IC50 for SP2509 was found to be in the submicromolar range across cell lines with SP2577 being more potent. A-673 and TC-71 were 5-10 fold less sensitive than RD-ES and TC-32. Agents currently utilized in clinic were universally active at clinically achievable concentrations and exposure times. Combinations showed additivity frequently and demonstrated promising activity that can be used to inform further decision making once LSD1 inhibition toxicities are better known. These findings suggest potentially promising opportunities for developing combination clinical trials to maximize development of LSD1 inhibitors.
Citation Format: Darcy Welch, Elliot Kahen, Christopher L. Cubitt, Damon R. Reed. LSD1 inhibition alone and in combination with chemotherapy in Ewing sarcoma cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2034. doi:10.1158/1538-7445.AM2017-2034
Abstract 2037: Oral nitroxoline in combination with intravesical bacille calmette-guerin (BCG) shows synergistic antitumor efficacy in mouse bladder cancer orthotopic xenograft
Authors: Li Qiang , Pan Kevin , Li Xiezhao , Xu Naijin , Huang Peng 
Published: July 2017

Abstract
Nitroxoline, an antibiotic used to treat urinary tract infection, had previously been identified as a MetAP2 inhibitor and found to show antitumor efficacy in mouse models of human breast cancer xenograft and bladder cancer orthotopic xenograft [1]. Our purpose in this study was to evaluate the feasibility of combining oral nitroxoline with intravesical BCG, the first-line therapy for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC), in mouse bladder cancer orthotopic xenograft. The luciferase-expressing murine bladder cancer cell line MBT-2-Luc cells was transurethrally implanted in the bladder of syngeneic female C3H/He mice. The animals were randomly divided into groups and treated with phosphate-buffered saline (PBS), oral nitroxoline, intravesical BCG alone, and a combination as described in methods. The IVIS spectrum images analyses of luciferin-stained tumor at 21 days after inoculation revealed that combining oral nitroxoline with intravesical BCG showed synergistically enhanced antitumor efficacy and prolonged long-term survival, implicating the potential of combining bladder cancer treatment using oral nitroxoline with intravesical BCG in the clinical setting. The mechanism behind this observation is currently under investigated.
Citation Format: Qiang Li, Kevin Pan, Xiezhao Li, Naijin Xu, Peng Huang. Oral nitroxoline in combination with intravesical bacille calmette-guerin (BCG) shows synergistic antitumor efficacy in mouse bladder cancer orthotopic xenograft [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2037. doi:10.1158/1538-7445.AM2017-2037
Abstract 2038: Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies
Authors: Makena Monish Ram , Koneru Balakrishna , Kang Min H. , Reynolds C. Patrick 
Published: July 2017

Abstract
Introduction: T-cell lymphoid malignancies (TCLMs) are in need of novel and more effective therapies. Romidepsin is a histone deacetylase (HDAC) inhibitor that achieved FDA registration as 2nd line therapy for peripheral and cutaneous T-cell lymphomas. The cytotoxic retinoid fenretinide achieved durable complete responses against T-cell lymphomas in early-phase clinical trials and T-cell lymphoma patients who failed prior romidepsin treatment responded to fenretinide. Fenretinide is currently being evaluated in a Phase IIa clinical trial for relapsed/refractory PTCL patients (NCT02495415). We investigated the potential for using these two agents in combination in TCLMs. Methods and Results: Using the DIMSCAN assay, we demonstrated cytotoxic synergy between romidepsin and fenretinide in fifteen TCLM cell lines at clinically-achievable concentrations that lacked cytotoxicity for non-malignant cells (fibroblasts and blood mononuclear cells). In vivo, romidepsin + fenretinide + ketoconazole (enhances fenretinide exposures by inhibiting fenretinide metabolism) showed greater activity in subcutaneous (COG-LL-317m and TX-LY-183x PDX) and disseminated (COG-LL-317m Luc expressing the luciferase gene) TCLM xenograft models than single agent romidepsin or fenretinide + ketoconazole. Fenretinide + romidepsin caused a reactive oxygen species (ROS, measured by DCFDA dye)-dependent increase in pro-apoptotic proteins (Bim, tBid, Bax and Bad), apoptosis (via TUNEL assay), and inhibition of HDAC enzymatic activity, which achieved a synergistic increase in histone acetylation. The synergistic cytotoxicity, apoptosis, and histone acetylation of fenretinide + romidepsin was abrogated by antioxidants (vitamins C or E). Romidepsin + fenretinide activated p38 and JNK via ROS, and shRNA knockdown of p38 and JNK1 significantly decreased the synergistic cytotoxicity and apoptosis. Romidepsin + fenretinide also showed synergistic cytotoxicity for B-lymphoid malignancy cell lines, but did not increase ROS, acetylation of histones, activation of p38 + JNK, or cytotoxicity in fibroblasts and blood mononuclear cells. Conclusion: Romidepsin + fenretinide achieved synergistic activity in preclinical models of TCLMs, but not in non-malignant cells, via a novel molecular mechanism. These data support conducting clinical trials of romidepsin + fenretinide in relapsed and refractory TCLMs.
Citation Format: Monish Ram Makena, Balakrishna Koneru, Min H. Kang, C. Patrick Reynolds. Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2038. doi:10.1158/1538-7445.AM2017-2038
Abstract 2042: Nano-tetraiodothyroacetic acid (NDAT) potentiates gefitinib-induced antiproliferation in colorectal cancer cells by inhibiting EGFR sialylation and PI3K activation
Authors: Chin Yu-Tang , Lin Chi-Yu , Changou Chun A. , Whang-Peng Jacqueline , Davis Paul J. , Lin Hung-Yun 
Published: July 2017

Abstract
The resistance of gefitinib has been revealed to complicate cancer therapy. Tetraiodothyroacetic acid (tetrac) and its nanoparticulate derivative (NDAT, nano-tetrac) have been proved in vitro and in vivo xenograft demonstrating anti-proliferative and anti-angiogenetic activities. It also indicates that they potentiate anti-cancer agent-induced anti-proliferation in cancer cells. In this study, we investigated the effects of NDAT on gefitinib-induced anti-cancer activities in human colorectal cancer cells. Gefitinib inhibited cell proliferation at concentration 1 μM in K-ras wild type HT29 cell and NDAT enhanced the anti-proliferation-induced gefitinib significantly. Meanwhile, both inhibited proliferative and metastatic genes expression in HT29 cells. On the other hand, 10 μM gefitinib inhibited cell proliferation in K-ras mutant HCT116 cell which was further enhanced by NDAT. Different from results in HT-29 cells, only NDAT inhibited proliferative and metastatic genes expression significantly and enhanced the effect of gefitinib in HCT116 cells. ST6Gal-1 catalyzes sialylation of EGFR and induces gefitinib-resistant in colorectal cancers. In addition, NDAT did reduced not only ST6Gal-1 gene expression, but also its protein production. However, the inhibition of ST6Gal-1 expression may not be sufficient to induced anti-proliferation in colorectal cancer cells. PI3K inhibitor, LY294002, was able to potentiate the gefitinib-induced anti-proliferation in
HCT116 cells suggesting that constitutive activation of PI3K may play a key role on gefitinib-resistance in HCT116 cells. In summary, NDAT potentiated gefitinib-induced anti-proliferation via inhibiting the activity of ST6Gal-1 and PI3K activation in gefitinib-resistant colorectal cancer cells.
Citation Format: Yu-Tang Chin, Chi-Yu Lin, Chun A. Changou, Jacqueline Whang-Peng, Paul J. Davis, Hung-Yun Lin. Nano-tetraiodothyroacetic acid (NDAT) potentiates gefitinib-induced antiproliferation in colorectal cancer cells by inhibiting EGFR sialylation and PI3K activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2042. doi:10.1158/1538-7445.AM2017-2042